Summary
- Danaher is a financial performance leader in healthcare equipment and diagnostics.
- The coronavirus pandemic and refocus by investors on medical-related companies have benefited the company's valuation.
- Strong technical buying momentum in the shares has continued in September and October.
Danaher (NYSE:DHR) has been near the top of my momentum screens most of 2020. Is the company growing like gangbusters? No. Is a takeover bid imminent? No. Is there a growth catalyst or new product about to launch sales and profits into the stratosphere? No, none that I am aware of. So, why is the quote a steady and robust winner? The explanation may be as simple as a supply/demand imbalance in the shares.
The stock is a leading performer in the medical/healthcare equipment category during 2020. Its diagnostic, research and chemical screening tools are used in the water treatment business, at hospitals and pharma research facilities globally, plus physician offices and life science laboratories to name just a few customers. The medical sector on Wall Street has been under heavy investor accumulation this year with stable revenues, high margins and a growth-based future, faring better than other U.S. industries in recession. The health-related coronavirus pandemic has been the primary decision catalyst fueling investor enthusiasm.
Below is a 52-week price graph comparison, measuring Danaher against rivals and peers Thermo Fisher Scientific (NYSE:TMO), Agilent (NYSE:A), Abbott Labs (NYSE:ABT), Laboratory Corp (NYSE:LH), Becton, Dickinson (NYSE:BDX) and the S&P 500 index. Danaher and Thermo Fisher have been the standout winners. I have mentioned Abbott here and Thermo here in bullish articles during the summer on Seeking Alpha.

Danaher has outperformed the S&P 500 index by nearly +40% the last 12 months of trading. In a June 3rd story, I talked about the name as a Top 10 momentum pick from the mega-capitalization area of the market. Does strong past performance guarantee Danaher’s rapid advance will continue into 2021? No. In fact, a pullback in this stock with the rest of the stretched equity market is overdue. After the record +50% rise in the market averages off the pandemic lows in March, a period of negative price action should be expected. However, Danaher’s defensive characteristics could support the price better than a huge list of other individual names.

